Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study - Archive ouverte HAL Access content directly
Journal Articles Molecular Biology Reports Year : 2022

Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study

(1) , (1) , (1) , (1) , (2) , (3) , (1) , (1)
1
2
3

Abstract

Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection course. Antidiabetic drugs such as sodium-glucose transporter-2 (SGLT-2) inhibitors have garnered substantial attention recently due to their efficacy in reducing the severity of cardiorenal disease. The effect of SGLT-2 inhibitors in patients with COVID-19 remains unclear particularly since SGLT-2 inhibitors contribute to altering the RAAS cascade activity, which includes ACE-2, the major cell entry receptor for SARS-CoV2. A study, DARE-19, was carried out to unveil the effects of SGLT-2 inhibitor treatment on comorbid disease complications and concomitant COVID-19 outcomes and demonstrated no statistical significance. However, the need for further studies is essential to provide conclusive clinical findings.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03627229 , version 1 (01-04-2022)

Identifiers

Cite

Diala Alhaj Moustafa, Zainab Imran, Roua Ismail, Menatallah Rayan, Alain-Pierre Gadeau, et al.. Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study. Molecular Biology Reports, 2022, 49 (3), pp.2321-2324. ⟨10.1007/s11033-022-07183-w⟩. ⟨inserm-03627229⟩

Collections

INSERM CNRS U1034
9 View
10 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More